A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man.

Abstract:

:The metabolic fate and ACTH-suppressant activity of two injectable dexamethasone esters, 21-phosphate and 21-sulphate, were studied in healthy men. After i.v. injection of 20mg free steroid alcohol, dexamethasone phosphate was efficiently hydrolyzed to free dexamethasone, reaching its peak plasma concentration within 5 min. About 9% of the administered dose appeared in the urine as free dexamethasone. By contrast, virtually no free dexamethasone was found in plasma and urine after injection of dexamethasone sulphate. Pharmacokinetic analysis showed that dexamethasone sulphate had a shorter plasma half-life and a higher metabolic clearance rate than free dexamethasone. A larger fraction (60%) of dexamethasone sulphate was rapidly excreted unmetabolized in urine. The plasma cortisol level was significantly suppressed for more than 24h after dexamethasone phosphate, while the plasma cortisol profile after dexamethasone sulphate merely showed physiological circadian variations. When the steroid esters were injected after pretreatment with metyrapone, a definite suppression of plasma ACTH was noted after dexamethasone phosphate, but again, dexamethasone sulphate was ineffective. These results cast serious doubt on the clinical value of dexamethasone sulphate as an injectable glucocorticoid, and critical reevaluation of this preparation is needed.

journal_name

Eur J Clin Pharmacol

authors

Miyabo S,Nakamura T,Kuwazima S,Kishida S

doi

10.1007/BF00618778

subject

Has Abstract

pub_date

1981-01-01 00:00:00

pages

277-82

issue

4

eissn

0031-6970

issn

1432-1041

journal_volume

20

pub_type

杂志文章
  • Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people.

    abstract:PURPOSE:This study aims to compare the prevalence of potentially inappropriate medicines (PIMs) and potential prescribing omissions (PPOs) using several screening tools in an Irish community-dwelling older cohort, to assess if the prevalence changes over time and to determine factors associated with any change. METHOD...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-015-1815-1

    authors: Moriarty F,Bennett K,Fahey T,Kenny RA,Cahir C

    更新日期:2015-04-01 00:00:00

  • Effect of itraconazole on cerivastatin pharmacokinetics.

    abstract:OBJECTIVE:To determine the effects of itraconazole, a potent inhibitor of CYP3A4, on the pharmacokinetics of cerivastatin, a competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. METHODS:A randomized, double-blind, cross-over study design with two phases, which were separated by a washout pe...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s002280050566

    authors: Kantola T,Kivistö KT,Neuvonen PJ

    更新日期:1999-01-01 00:00:00

  • Drug-associated non-pyrogenic hyperthermia: a narrative review.

    abstract:PURPOSE:Hyperthermia occurs when heat accumulation surpasses the body's ability for heat dissipation. Many drugs may affect thermoregulation. This narrative review aimed to provide an overview of the current literature concerning reports of drug-associated non-pyrogenic hyperthermia. METHODS:A comprehensive search was...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00228-019-02763-5

    authors: Bongers KS,Salahudeen MS,Peterson GM

    更新日期:2020-01-01 00:00:00

  • Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.

    abstract:PURPOSE:To assess the influence of the P450 oxidoreductase 28 SNP (POR 28) on tacrolimus pharmacokinetics in the Chinese population. METHODS:Seventy-one healthy Chinese volunteers enrolled in the study received an oral dose of 2 mg of tacrolimus after providing written informed consent. CYP3A5 3 was genotyped by polym...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00228-012-1432-1

    authors: Zhang JJ,Zhang H,Ding XL,Ma S,Miao LY

    更新日期:2013-04-01 00:00:00

  • Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients.

    abstract:OBJECTIVE:The aim of this study was to define the pharmacokinetic profile of free carbamazepine (F-CBZ) in adult Omani epileptic patients in order to improve on dosing schedules through population pharmacokinetic analysis using the NONMEM program. METHOD:Steady-state trough F-CBZ serum concentrations, carbamazepine (C...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002280100300

    authors: Deleu D,Aarons L,Ahmed IA

    更新日期:2001-06-01 00:00:00

  • Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.

    abstract:OBJECTIVE:In vitro studies with human liver microsomes have suggested that the oxidative conversion of mexiletine (MX) to its metabolites is catalyzed by CYP2D6 and is significantly impaired in microsomes with the CYP2D6*10/*10 genotype. Therefore, we examined the influence of the CYP2D6*10 allele on MX pharmacokinetic...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00228-003-0656-5

    authors: Otani M,Fukuda T,Naohara M,Maune H,Senda C,Yamamoto I,Azuma J

    更新日期:2003-09-01 00:00:00

  • Trials, Regulation and tribulations.

    abstract:INTRODUCTION:Regulation EU 536/2014 EU introduces a separation between two parts (technical-scientific aspects and locally relevant ethical aspects) in the assessment of applications for approval of trials and provides for each 'Member State concerned' to arrive at 'one single decision' regarding the application for au...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-016-2009-1

    authors: Petrini C,Garattini S

    更新日期:2016-04-01 00:00:00

  • Impaired cimetidine absorption due to antacids and metoclopramide.

    abstract::In 8 healthy subjects the absorption of cimetidine was investigated when given alone, together with 60 ml aluminium/magnesium hydroxide containing antacid (neutralising capacity 26 mmol HCl/10 ml), and together with liquid metoclopramide 14 mg. The antacid significantly (P less than 0.01) reduced the bioavailability (...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00544602

    authors: Gugler R,Brand M,Somogyi A

    更新日期:1981-01-01 00:00:00

  • Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men.

    abstract::Verapamil, 0.1 mg/kg body wt, was injected i.v. over 2 minutes in 8 subjectively healthy middle-aged men, followed by a continuous infusion of 0.007 mg/kg body wt per minute. Prior to the injection several of the subjects had raised pulmonary or systemic arterial pressures. At rest, the central pressures increased sli...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00562656

    authors: Atterhög JH,Ekelund LG

    更新日期:1975-06-13 00:00:00

  • Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.

    abstract:OBJECTIVE:The purpose of this study was to investigate in healthy male subjects the tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of clazosentan, an intravenous endothelin receptor antagonist. METHODS:Clazosentan was infused at doses of 3-60 mg/h for 3 h, 60 mg/h for 6 h and at 30 mg/h for 12...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-006-0117-z

    authors: van Giersbergen PL,Dingemanse J

    更新日期:2007-02-01 00:00:00

  • Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.

    abstract:BACKGROUND:Visual hallucinations (VHs) are frequent non-motor complication of Parkinson's disease (PD), associated to a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and psychosis in Alzheimer's disease, addictions, schizophrenia, and bipolar disorder. Howe...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-016-2111-4

    authors: Ferrari M,Comi C,Marino F,Magistrelli L,De Marchi F,Cantello R,Riboldazzi G,Bono G,Cosentino M

    更新日期:2016-11-01 00:00:00

  • Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate.

    abstract::The pharmacokinetics of isosorbide-5-mononitrate (IS-5-MN) has been studied in two groups of healthy volunteers after oral (n = 20) and intravenous (n = 11) administration of 20 mg, which had previously been proved to be as effective as 20 mg sustained-release isosorbide dinitrate (ISDN). IS-5-MN in serum was measured...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00618777

    authors: Abshagen U,Betzien G,Endele R,Kaufmann B

    更新日期:1981-01-01 00:00:00

  • Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure.

    abstract:INTRODUCTION:Epidural hydromorphone could be useful in obstetric analgesia as there is a need for a more water-soluble opioid than sufentanil or fentanyl with prolonged analgesic effect. To our knowledge, the pharmacokinetics of epidural hydromorphone has not been evaluated in parturients. MATERIALS AND METHODS:In thi...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-020-02880-6

    authors: Puhto T,Kokki M,Hakomäki H,Spalding M,Gunnar T,Alahuhta S,Vakkala M

    更新日期:2020-07-01 00:00:00

  • Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium.

    abstract::The linearity of the pharmacokinetics of the metamizol metabolites 4-methyl-amino-antipyrine (4-MAA), 4-amino-antipyrine (4-AA), 4-formyl-aminoantipyrine (4-FAA), and 4-acetyl-amino-antipyrine (4-AcAA) has been studied after administration to 15 healthy male volunteers of single oral doses of 750, 1500, and 3000 mg me...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00314805

    authors: Vlahov V,Badian M,Verho M,Bacracheva N

    更新日期:1990-01-01 00:00:00

  • Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.

    abstract:OBJECTIVE:The aim of this investigation was to clarify the stereoselective properties in lansoprazole metabolism by monitoring the metabolic consumption for each enantiomer and the formation of the main metabolites, lansoprazole sulfone and 5-hydroxylansoprazole, in the presence of human liver microsomal enzymes. METH...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002280100374

    authors: Katsuki H,Hamada A,Nakamura C,Arimori K,Nakano M

    更新日期:2001-12-01 00:00:00

  • Differences in the bioavailability of dihydrotachysterol preparations.

    abstract::The bioavailability of four preparations containing dihydrotachysterol (DHT2) was tested in two separate trials with administration of single, oral doses of 1 mg per individual. The relative bioavailability of corresponding preparations (capsules vs capsules and oral solution vs oral solution) was tested in a randomis...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00193484

    authors: Koytchev R,Alken RG,Vagaday M,Kunter U,Kirkov V

    更新日期:1994-01-01 00:00:00

  • Allele and genotype frequency of CYP2C9 in Tamilnadu population.

    abstract:OBJECTIVES:To identify the frequency of CYP2C9*1, *2 and *3 alleles and the genotype of CYP2C9 gene in the Tamilian population. METHODS:The study was conducted on 135 unrelated healthy human volunteers. DNA was extracted from the peripheral leukocytes samples and was analyzed using the polymerase chain reaction (PCR)-...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-003-0666-3

    authors: Adithan C,Gerard N,Vasu S,Balakrishnan R,Shashindran CH,Krishnamoorthy R

    更新日期:2003-11-01 00:00:00

  • Lack of effect of amoxycillin on the absorption of ofloxacin.

    abstract::Amoxycillin and ofloxacin are both well absorbed after oral administration, despite being hydrophilic. We have studied the possibility of competition between these two drugs for a carrier-mediated transport system, since both drugs are absorbed by saturable processes in the rat small intestine. Oral doses of amoxycill...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00315484

    authors: Paintaud G,Alván G,Hellgren U,Nilsson-Ehle I

    更新日期:1993-01-01 00:00:00

  • The pharmacokinetics of clonidine in high dosage.

    abstract::We have evaluated the pharmacokinetics of high doses of clonidine, as used in the prophylactic treatment of alcohol withdrawal syndrome, in 11 alcohol-dependent patients undergoing surgery for oesophagogastrectomy. Clonidine was given in a bolus of 150 micrograms followed by a continuous infusion. After a mean period ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00315500

    authors: Fauler J,Verner L

    更新日期:1993-01-01 00:00:00

  • Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline.

    abstract::A cross-over study of kinetics has been undertaken in 12 healthy adults volunteers using two sustained-release theophylline products that allow once a day dosing (Theo-Dur tablets and Dilatrane A.P. bead filled capsules) to compare the i.v. pharmacokinetic profiles when taken with an hyperlipidic meal and a balanced s...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00609431

    authors: Brazier JL,Benchekroun Y,Gillet A,Andre C

    更新日期:1989-01-01 00:00:00

  • Fluocortolone: pharmacokinetics and effect on ACTH and cortisol secretion during daily and alternate-day administration.

    abstract::The pharmacokinetics of fluocortolone and its effect on the circadian rhythm of plasma cortisol and ACTH have been studied during different schedules of oral administration. Groups of 6 healthy male adults were given a single daily dose of fluocortolone 5, 10 and 20 mg, and another group received 20 mg every second da...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00609249

    authors: Tüber U,Posern U,Bickel U,Matthes H,Voigt K

    更新日期:1988-01-01 00:00:00

  • Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.

    abstract:PURPOSE:Fibroblast growth factor receptor 4 (FGFR4) expression has association with tumor malignancy. In thyroid cancers, FGFR4 has been reported to be characteristically expressed in aggressive thyroid tumors, such as anaplastic thyroid carcinoma (ATC). METHODS:We investigated FGFR4 expression in patients with ATC an...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-020-02842-y

    authors: Yamazaki H,Yokose T,Hayashi H,Iwasaki H,Osanai S,Suganuma N,Nakayama H,Masudo K,Rino Y,Masuda M

    更新日期:2020-05-01 00:00:00

  • A real or apparent decrease in glomerular filtration rate in patients using olaparib?

    abstract:PURPOSE:Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for ovarian and metastatic breast cancer. Increased serum creatinine levels have been observed in patients taking olaparib, but the underlying mechanism is unknown. This study aimed to investigate if patients receiving olaparib have increased...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-020-03070-0

    authors: Bruin MAC,Korse CM,van Wijnen B,de Jong VMT,Linn SC,van Triest B,Rosing H,Beijnen JH,van den Broek D,Huitema ADR

    更新日期:2021-02-01 00:00:00

  • Paracetamol disposition and metabolite kinetics in patients with chronic renal failure.

    abstract::The disposition of paracetamol following an oral dose of 1.0 g was compared in 10 healthy volunteers, 7 patients with moderate chronic renal failure and 6 patients with end stage renal failure on maintenance haemodialysis. Paracetamol absorption was normal in the patients with renal failure. The mean plasma half-life ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00558162

    authors: Prescott LF,Speirs GC,Critchley JA,Temple RM,Winney RJ

    更新日期:1989-01-01 00:00:00

  • Increased psychotropic drug consumption by children in the Netherlands during 1995-2001 is caused by increased use of methylphenidate by boys.

    abstract:OBJECTIVE:The aim of the study was to determine the changes in consumption of psychotropic drugs by children aged less than 18 years during the years 1995 to 2001 in the Netherlands. METHODS:The year prevalence of antipsychotics, benzodiazepines, antidepressants and psychostimulants for boys and girls under 18 years w...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-004-0765-9

    authors: Hugtenburg JG,Heerdink ER,Egberts AC

    更新日期:2004-07-01 00:00:00

  • Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.

    abstract::In 10 healthy male subjects the pharmacokinetics and haemodynamic effects of sustained-release isosorbide-5-mononitrate 60 mg (IS-5-MN) were studied after oral administration at two different times in the day (08.00 h and 20.00 h). Effects on blood pressure and heart rate after 3 min standing upright were measured in ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00315142

    authors: Lemmer B,Scheidel B,Blume H,Becker HJ

    更新日期:1991-01-01 00:00:00

  • Delayed elimination of triamterene and its active metabolite in chronic renal failure.

    abstract::The kinetics of triamterene and its active phase II metabolite were studied in 32 patients with various degrees of impaired renal function; the creatinine clearances ranged from 135 to 10 ml/min. The area under the plasma concentration-time curves (AUC) for triamterene were not influenced by kidney function, but the A...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00609885

    authors: Knauf H,Möhrke W,Mutschler E

    更新日期:1983-01-01 00:00:00

  • The H1-antagonist mequitazine: studies on performance and visual function.

    abstract::The effects of single oral doses of mequitazine (5 and 10 mg), terfenadine (60 mg) and triprolidine (10 mg) as active controls, and placebo were evaluated on visuo-motor coordination, digit symbol substitution, critical flicker fusion and dynamic visual acuity, and on subjective assessments of mood and well-being in s...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00542129

    authors: Nicholson AN,Stone BM

    更新日期:1983-01-01 00:00:00

  • Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination.

    abstract::Potentiation of the anticoagulant-effect of warfarin by amiodarone was studied in 30 patients. Thirteen received both drugs concurrently, and 17 received warfarin alone and the combination sequentially. Warfarin doses were adjusted to maintain the prothrombin time between 25-30% of control and its kinetics were compar...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00543320

    authors: Almog S,Shafran N,Halkin H,Weiss P,Farfel Z,Martinowitz U,Bank H

    更新日期:1985-01-01 00:00:00

  • Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.

    abstract:PURPOSE:Bosutinib is an oral, dual Src and Abl tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to prior TKI therapy. Bosutinib is primarily metabolized by cytochrome P450 (CYP) 3A4, suggesting drug interaction potential with...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-016-2108-z

    authors: Hsyu PH,Pignataro DS,Matschke K

    更新日期:2017-01-01 00:00:00